

8/7/1 (Item 1 from file: 351)
DIALOG(R)File 351:Derwent WPI
(c) 2004 Thomson Derwent. All rts. reserv.

008815765

WPI Acc No: 1991-319778/**199144**

New water-soluble polypeptide(s) with affinity for IFN-alpha and beta -
used to treat e.g. lupus erythematosus, Behcet's disease, aplastic
anaemia, diabetes mellitus, rheumatoid arthritis, etc.

Patent Assignee: LAB EURO BIOTECHNO (EUBI-N)

Inventor: EID P; GRESSER I; LUTFALLA G; MEYER F; MOGENSEN K E; TOVEY M G;
UZE G

Number of Countries: 001 Number of Patents: 001

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
FR 2657881	A	19910809	FR 901298	A	19900205	199144 B

Priority Applications (No Type Date): FR 901298 A 19900205

Abstract (Basic): FR 2657881 A

A water soluble polypeptide (I) which has a high affinity for IFN-alpha and IFN-beta is claimed. (I) has the formula given in the specification and may contain a deletion. Also claimed are (I) hybridised to another polypeptide (2) a DNA, sequence encoding (I) cells expressing (I) cells expressing (I) bound to (2) and a process for prep. (I) by cultivating the appropriate cells in a nutrient medium. (2) slows down the degradation of (I) in humans and is an Ig pref. IgG1.

USE/ADVANTAGE - (1) and (2) are used as diagnostic agents and to prepare antibodies to IFN-alpha and IFN-beta (claimed). Compsns. contg. (1) and (2) are used to treat conditions associated with abnormal IFN-alpha and IFN-beta prodn. e.g. lupus erythematosus, Behcet's disease, aplastic anaemia, diabetes, mellitus, plaque sclerosis, rheumatoid arthritis or serious immunodeficiency diseases e.g. AIDS and organ graft rejections. Admin. is parenteral, subcutaneous, intravenous, intramuscular or intralesional. Dosage is 1-5 mg/kg/day. (1) and (2) in their purified form can be used to determine the tertiary structure of IFN-alpha and beta at their sites of fixation. This can be useful as a model for the synthesis of antagonists which would have immunosuppressant, antiviral or antitumoural use.

Dwg.0/0

Derwent Class: B04; D16

International Patent Class (Additional): A61K-037/02; A61K-043/00;
C12N-015/11; C12P-021/00; G01N-033/68